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Summary
The Swiss societies of Infectious Diseases, Pediatric Car-
diology and Cardiology and the Pediatric Infectious Dis-
ease Group of Switzerland present the current update on
infective endocarditis prophylaxis in a joint initiative. The
major focus of the revised recommendations is a compre-
hensive prevention campaign for all patients at risk for in-
fective endocarditis. Antibiotic prophylaxis is recommend-
ed only for individuals at high risk. Within this high-risk
group there is a ranking order, and the conditions are pre-
sented accordingly. Antibiotic prophylaxis is no longer rec-
ommended for patients with unrepaired ventricular septal
defects and patent ductus arteriosus. Recommendations
for antibiotic prophylaxis for the prevention of infective en-
docarditis are categorized in dental and non-dental inter-
ventions.
Background and approach to guideline update
The Swiss Society for Infectious Diseases (SSI), with the
support of the Federal Office of Public Health, initiated
a platform for clinical practice guidelines in 2017. The
goal of these guidelines is to optimise and possibly reduce
antibiotic use in Switzerland [1]. After considerable revi-
sion of the previous guidelines on infective endocarditis
prophylaxis by the American Heart Association in 2007,
the Swiss recommendations were revised and published in
2008 [2]. The SSI and the Swiss Society of Cardiology
together with the Swiss Society for Paediatric Cardiology
and the Paediatric Infectious Disease Group of Switzerland
are presenting the current update as a joint initiative. Fol-
lowing the standard procedure of establishing SSI guide-
lines, the expert group reviewed existing and published
international guidelines and selected one of them as the
designated reference guidelines. For the subject “Preven-
tion of Infective Endocarditis”, the recommendations of
the European Society of Cardiology (ESC) 2015 were se-
lected [3]. Deviations in the wording of the text and adap-
tation of the recommendations in accordance with the
Swiss health care system were formulated by the expert
group and concisely presented as the “Swiss Guideline
Digest”. This summary is freely available on the web
(https://ssi.guidelines.ch/ → Infective Endocarditis/Pre-
vention).
Prevention and prophylaxis
Traditionally, either the term “antibiotic prophylaxis” or
“endocarditis prophylaxis” is used to mean the administra-
tion of an antimicrobial agent prior to an intervention (e.g.,
in dental medicine). The goal of antibiotic prophylaxis is
the rapid elimination of a transitory bacteraemia that can
occur during an intervention. Hence, the aim is to reduce
the risk of developing infective endocarditis. Several stud-
ies have indicated, however, that only a small proportion of
cases of infective endocarditis are associated with a previ-
ous dental intervention and that the association of infective
endocarditis with skin or mucosal injuries through daily
activities appears to have a much higher impact on the total
number of infective endocarditis cases. This observation
prompted the providers of national and international guide-
lines to focus on general prevention strategies, including
comprehensive patient education about the potential risks
of developing an infective endocarditis and recommenda-
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tions for skin and dental hygiene precautions. Thus, the ter-
minology “prevention and prophylaxis” is important and
should be used in future.
Antibiotic prophylaxis is indicated for only one
risk group
Depending on the severity of the heart disease and valvu-
lopathy, the risk for infective endocarditis is categorised as
moderate (or intermediate) or high [4]. After the indica-
tion for antibiotic prophylaxis was restricted to only one
risk group (i.e., those at high risk for infective endocardi-
tis), studies from England reported a reduction in antibiotic
prescriptions and an increase in the incidence of infective
endocarditis [5, 6]. Consequently, the results of these stud-
ies were discussed again, and broadening the indication
for antibiotic prophylaxis was also considered [7, 8]. Con-
versely, other studies during the same period did not ob-
serve an increase in the incidence of infective endocarditis
[9, 10]. Moreover, recent large epidemiological studies in
the United States [11] and Europe [12] demonstrated that –
despite changes in antibiotic prophylaxis guidelines – the
incidence of infective endocarditis remained stable from
1998 to 2013 and 1990 to 2014, respectively. In agree-
ment with the ESC 2015 guidelines, the Swiss expert group
recommends antibiotic prophylaxis only for individuals at
high risk and hence, for only one risk group. This recom-
mendation has been valid in Switzerland since 2008 and
continues to be so.
What is new in comparison to the recommen-
dations in 2008?
Among those in the high-risk group, patients with a history
of infective endocarditis and with a prosthetic heart valve,
or with a history of heart valve reconstruction and use of
foreign body material, have the highest risk of infection
[4]. Therefore, the indications for antibiotic prophylaxis
in the high-risk group are presented in a specific ranked
order. A few indications for antibiotic prophylaxis, previ-
ously listed in the 2008 recommendations, were removed
because of lack of evidence. These indications include
ventricle septum defect or open ductus arteriosus without
surgery.
Populations at high risk for infective endocarditis
1. Patients with a previous episode of infective endo-
carditis.
2. Patients with any prosthetic valve (biological or me-
chanical), including a transcatheter valve (tran-
scatheter valve implantation), or those in whom any
prosthetic material was used for cardiac valve repair.
3. Patients with congenital heart disease (CHD):
Any type of cyanotic CHD (i.e., unrepaired CHD).
Any type of CHD repaired with prosthetic material,
whether placed surgically or by percutaneous tech-
niques. ⇒ At risk for up to 6 months after the proce-
dure.
Any type of CHD repaired with prosthetic material,
whether placed surgically or by percutaneous tech-
niques. ⇒ At lifelong risk if residual shunt persists or
if residual finding persists after the procedure (e.g., in-
complete tissue ingrowth of prosthetic material).
4. There is no evidence to recommend antimicrobial pro-
phylaxis for cardiac transplant recipients who develop
cardiac valvulopathy. The indication should be dis-
cussed on a case-by-case basis. The patient should
contact their transplant specialist to evaluate the indi-
cation prior to an elective intervention.
Dental and non-dental interventions
Antibiotic prophylaxis recommendations for interventions
related to ear-nose-throat surgery, the skin, the respiratory
tract, the gastrointestinal tract and the urogenital tract are
not part of the specific antibiotic endocarditis prophylaxis
recommendations for two reasons. First, most abdominal
and gynaecological surgical interventions are performed in
a hospital setting, and Swissnoso has published recommen-
dations for perioperative antibiotic prophylaxis [13] that
apply to all patients, including those with an elevated risk
for infective endocarditis. A few exceptions for high-risk
patients are published on the SSI website (https://ssi.guide-
lines.ch/ → Infective Endocarditis/Prevention, Box 3),
such as antibiotic treatment for incision of a skin abscess,
or antimicrobial agent options for abdominal surgery (i.e.,
amoxicillin/clavulanic acid instead of cefuroxime or cefa-
zolin to cover activity against Enterococcus spp.). Second,
the Swiss Society for Gastroenterology published specif-
ic antibiotic prophylaxis recommendations for endoscopic
interventions [14]. For these reasons, recommendations for
an endocarditis card (similar to an allergy passport carried
by patients) is limited to dental interventions. For non-den-
tal interventions, we refer to published recommendations
of various societies [13, 14] and those of the SSI (list be-
low and https://ssi.guidelines.ch/ → Infective Endocardi-
tis/Prevention).
Dental procedures
Antibiotic prophylaxis is not recommended for local
anaesthetic injections in non-infected tissues, treatment of
superficial caries, removal of sutures, dental X-rays, place-
ment or adjustment of removable prosthodontic or ortho-
dontic appliances or braces, the period following the shed-
ding of deciduous teeth, or superficial trauma to the lips
and oral mucosa.
Antibiotic prophylaxis should only be administered for
dental procedures with a tendency to bleed:
– requiring manipulation of the gingival or periapical re-
gion of the teeth
– perforation of the oral mucosa
Antibiotic prophylaxis prior to dental intervention and
dental hygiene*
The antibiotic prophylaxis should be taken 1 hour prior to
the intervention.
Amoxicillin
– Adults: 2 g p.o.
– Children: 50 mg/kg (maximum dose 2 g) p.o.
Alternatives in the case of penicillin allergy
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– Adults: cefuroxime-axetil 1 g p.o. in patients with de-
layed hypersensitivity reaction
– Children: cefuroxime-axetil 50 mg/kg p.o. (maximum
dose 1 g) in patients with delayed hypersensitivity reac-
tion
– Adults: clindamycin 600 mg p.o. in patients with imme-
diate hypersensitivity reaction
– Children: clindamycin 20 mg/kg p.o. (maximum dose
600 mg) in patients with immediate hypersensitivity re-
action
In the case of inability to swallow the antibiotic pill
– Adults: amoxicillin 2 g i.v.
– Children: amoxicillin 50 mg/kg i.v. (maximum dose 2
g)
Alternatives in the case of penicillin allergy and inability
to swallow the antibiotic pill
– Adults: cefazolin 1 g i.v. or ceftriaxone 2 g i.v. in pa-
tients with delayed hypersensitivity reaction
– Children: cefazolin 25 mg/kg i.v. (maximum dose 1 g)
or ceftriaxone 50 mg/kg i.v. (maximum dose 2 g) in pa-
tients with delayed hypersensitivity reaction
– Adults: clindamycin 600 mg i.v. or vancomycin 1 g i.v.
in patients with immediate hypersensitivity reaction
– Children: clindamycin 20 mg/kg i.v. (maximum dose
600 mg) or vancomycin 20 mg/kg i.v. (maximum dose
1 g) in patients with immediate hypersensitivity reac-
tion




– Antimicrobial perioperative prophylaxis is not recom-
mended for tonsillectomy in patients without risk for in-
fective endocarditis. There is no evidence-based recom-
mendation for antimicrobial perioperative prophylaxis
in patients with risk for infective endocarditis.
– Tonsillectomy is associated with bacteraemia in a con-
siderable proportion of patients undergoing this proce-
dure. There is no evidence that antimicrobial periopera-
tive prophylaxis prevents infective endocarditis in
patients at risk for infective endocarditis. The majority
of the expert group favours perioperative antimicrobial
prophylaxis for tonsillectomy in patients at high risk for
infective endocarditis. The agent should contain activi-
ty against microorganisms belonging to the oral flora.
– The expert group clearly categorises this statement as
an opinion and not as a guideline recommendation. The
expert group also states that the number of opinions
does not correlate with the level of evidence.
Respiratory tract procedures
– Antibiotic prophylaxis is not recommended for bron-
choscopy, laryngoscopy, or transnasal or endotracheal
intubation.
– For invasive procedures to treat an established infection
(e.g., drainage of abscess), an empirical antibiotic regi-
men containing anti-staphylococcal activity (Staphylo-
coccus aureus) should be used.
Gastrointestinal/genitourinary procedures
– Antibiotic prophylaxis is not recommended for gas-
troscopy, colonoscopy, low-risk laparoscopic proce-
dures on the biliary tract (see also recommendations for
antimicrobial perioperative prophylaxis of Swissnoso
2015), cystoscopy, vaginal or caesarean delivery, or
transoesophageal echocardiography.
– In the case of an established infection, an empiric an-
tibiotic regimen containing anti-enterococcal activity
should be used.
– If antibiotic therapy is indicated to prevent wound in-
fection or sepsis associated with a gastrointestinal or
genitourinary tract procedure, antimicrobial periopera-
tive or peri-interventional prophylaxis containing anti-
enterococcal activity should be used (see table 1, dose
recommendations are based on normal renal and liver
function).
Skin and soft tissue procedures
– Antibiotic prophylaxis is not recommended for any pro-
cedure.
– For surgical procedures on infected skin/skin structures
(e.g., incision of a skin abscess), empirical antibiotic
should contain an agent with activity against staphylo-
cocci and beta-haemolytic streptococci.
Cardiac or vascular interventions
– Preoperative screening for nasal carriage of S. aureus is
recommended before elective cardiac surgery in order
to treat carriers.
– Systematic local treatment without screening for S. au-
reus is not recommended.
– Potential sources of infection (e.g., dental focus) should
be treated/removed ≥2 weeks prior to the intervention.
Table 1: Perioperative or peri-interventional antimicrobial prophylaxis for gastrointestinal/genitourinary procedures.
Perioperative antimicrobial prophy-
laxis
No allergy to penicillin Allergy to penicillin
Adults: 30–60 min before procedure,
single dose
Amoxicillin/clavulanate 2.2 g i.v. Vancomycin 1 g i.v.
plus gentamicin* 3 mg/kg i.v.
(or ciprofloxacin 400 mg i.v.)
plus metronidazole 500 mg i.v.
Children: 30–60 min before procedure,
single dose
Amoxicillin/clavulanate 50/5 mg/kg i.v.
(maximum 2.2 g. i.v.)
Vancomycin 20 mg/kg i.v. (maximum 1 g. i.v.)
plus gentamicin 2.5 mg/kg (maximum 80 mg) i.v.
plus metronidazole 10 mg/kg i.v. (maximum 500 mg i.v.)
– * As an alternative to gentamicin, another aminoglycoside (e.g., amikacin) can be administered. Kindly contact your institutional infectious diseases physician.
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Figure 1: Information and prevention strategy: prevention campaign for all patients at risk for infective endocarditis.
– Perioperative antibiotic prophylaxis is recommended
before placement of a pacemaker or implantable car-
dioverter defibrillator.
– Perioperative antibiotic prophylaxis should be adminis-
tered to patients undergoing surgical or transcatheter
implantation of a prosthetic valve, intravascular pros-
thetic device, or other foreign material (e.g., graft im-
plantation for endovascular aneurysm repair).
– Prophylaxis should be started immediately before the
procedure and repeated if the procedure is prolonged.
Prophylaxis should not be prolonged for more than 48
hours.
Areas of uncertainty
While developing the Swiss Digest recommendations, the
members of the expert group discussed the following areas
of uncertainty thoroughly.
Heart transplantation
Antibiotic prophylaxis in cardiac transplant recipients who
develop cardiac valvulopathy is not supported by evidence
and is not recommended by the ESC [3]. Conversely, the
International Society for Heart and Lung Transplantation
(ISHLT, 2010) recommends prophylaxis in cardiac trans-
plant recipients who develop cardiac valvulopathy [15].
Transplant patients have a high risk of developing tricuspid
regurgitation [16]; nonetheless, only a few (heterogeneous)
publications are available on tricuspid regurgitation and
the risk of developing infective endocarditis [17, 18]. The
rationale for the ISHLT recommendations (expert opinions
and consensus statement) relies on the observation of se-
vere clinical courses with a high mortality rate in transplant
patients with infective endocarditis [19]. The expert group
confirms that there is no scientific evidence to support a
recommendation for or against antibiotic prophylaxis in
cardiac transplant patients who develop valvulopathy. The
majority of the expert group members follow the recom-
mendations of the ESC 2015 [3]. At the same time, the ex-
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Figure 2: Patients with the highest risk for infective endocarditis require antibiotic prophylaxis prior to dental interventions. Only these patients
will also receive a separate antibiotic card. For non-dental interventions, specific recommendations can be found on the corresponding web-
sites.
pert group states that it is not meaningful to express a gen-
eralisable recommendation in Switzerland for a relatively
small patient population with (different) complex disease
histories. Because all heart transplant patients are followed
up in specialised institutions, it is the responsibility of the
treating transplant physician to prescribe antibiotic pro-
phylaxis prior to the intervention, as evaluated on a case-
by-case basis.
Tonsillectomy
Bacteraemia occurs frequently during tonsillectomy
[20–23]. However, perioperative antibiotic prophylaxis is
not recommended for tonsillectomy in patients without risk
for developing infective endocarditis [13, 24]. Because of
the lack of evidence, the ESC has not published any rec-
ommendations for patients with risk factors for develop-
ing infective endocarditis. The majority of the expert group
favour the administration of antimicrobial prophylaxis in
high-risk patients who are undergoing tonsillectomy [2, 23,
25]. The antimicrobial agent must have activity against or-
ganisms belonging to the oral microbiome (e.g., amoxi-
cillin 2 g or amoxicillin/clavulanic acid 2.2 g in adults, and
50 mg/kg [maximum dose 2.2 g] in children intravenous-
ly 30 minutes prior to incision). However, because of lack
of evidence, the expert group clearly categorises this state-
ment as expert opinion and not as guideline recommenda-
tions.
Information and communication strategy
The endocarditis prophylaxis recommendations presented
herein differ in only minor points in comparison to those
published in 2008. The revised recommendations mainly
relied on a comprehensive prevention campaign for all pa-
tients at risk for infective endocarditis (fig. 1).
The information strategy includes the following key ele-
ments:
– Knowledge transfer to increase awareness of good den-
tal and skin hygiene.
– Education about symptoms consistent with infective en-
docarditis and appropriate steps to take when these
symptoms occur (i.e., contact the doctor, obtain a blood
culture sample prior to administration of antibiotic ther-
apy).
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Considering that the rapid diagnosis and correct treatment
of infective endocarditis can be life-saving, patient edu-
cation is a central element in the prevention strategy. For
this reason, the Swiss expert group is collaborating with
the Swiss Heart Foundation. An information flyer that il-
lustrates the most important issues about infective endo-
carditis has been generated and is being distributed to all
patients at risk for infective endocarditis (fig. 1). The pur-
pose of this flyer is patient education and as a support-
ive instrument for caregivers and providers in the field of
heart disease. Patients at highest risk for infective endo-
carditis require antibiotic prophylaxis prior to certain den-
tal interventions, and only these patients will receive an
antibiotic card (fig. 1). Different versions of flyers and
cards are available for adults and children. For non-dental
interventions, specific recommendations can be found on
the corresponding websites (fig. 2). Additional patient in-
formation can also be found on the following websites:
https://www.endocarditis.ch [German] and
https://www.endocardite.ch [French]. Development of an
educational movie is in progress.
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